GSK Tries To Halt Teva's Generic Combivir Launch
GSK filed a motion for a preliminary injunction Friday in the U.S. District Court for the District of Delaware.
The company sued Teva in 2007, alleging that the proposed generic product would infringe a single GSK patent for Combivir, U.S. Patent Number 5,859,021, which is scheduled to expire in 2016.
The motion asks for an injunction barring Teva from making or selling...
To view the full article, register now.